Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

No longer available × Recurrence × loncastuximab tesirine × Clear all

Status

Recruiting 1 No longer available 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1

Interventions

zanubrutinib 1 sugemalimab 1 revumenib 1 loncastuximab tesirine 1 fludarabine phosphate 1 denileukin diftitox 1 Whole-Body Irradiation 1 Tacrolimus 1 Panobinostat 1 Mycophenolic Acid 1 Cytarabine 1 Cord Blood Stem Cell Transplantation 1 Busulfan 1 Bortezomib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04705454 2021-05-12

Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

ADC Therapeutics S.A.

No longer available

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡